Werewolf Therapeutics amends bylaws and elects three Class II directors at annual meeting

On June 21, 2023, the board of directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately to, among other things: • Amend certain procedures governing notice of each meeting of stockholders, including providing the record date for determining stockholders entitled to vote at the meeting; • Eliminate the former requirement regarding availability of the voting list during stockholder meetings, consistent with recent amendments to Section 219 of the Delaware General Corporation Law (the “DGCL”); • Clarify the procedures governing adjournment of the stockholder meetings, consistent with recent amendments to Section 222 of the DGCL; • Revise and enhance the procedures and disclosure requirements set forth in the advanced notice bylaw provision in connection with stockholder nominations of directors and submission of stockholder proposals,

The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain 29,895,437 3,279 1,400

The stockholders of the Company elected Meeta Chatterjee, Ph.D., Derek DiRocco, Ph.D., and Daniel J. Hicklin, Ph.D. as Class II directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2026. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Meeta Chatterjee, Ph.D. 18,766,485 4,810,351 6,323,280 Derek DiRocco, Ph.D. 18,471,357 5,105,479 6,323,280 Daniel J. Hicklin, Ph.D. 23,547,794 29,042 6,323,280